News & Events Year None201820172016201520142013201220112009 10/22/18 REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors 10/04/18 REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD 10/02/18 REGENXBIO to Present at the Chardan 2nd Annual Genetic Medicines Conference 09/06/18 REGENXBIO to Present at Upcoming Investor Conferences 08/30/18 REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease 08/14/18 REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 08/10/18 REGENXBIO Announces Pricing Of Public Offering Of Common Stock Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
